Lindbrook Capital LLC Purchases 5,202 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Lindbrook Capital LLC lifted its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 470.3% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,308 shares of the pharmaceutical company's stock after acquiring an additional 5,202 shares during the quarter. Lindbrook Capital LLC's holdings in Vertex Pharmaceuticals were worth $3,058,000 at the end of the most recent reporting period.

Other institutional investors also recently added to or reduced their stakes in the company. Quent Capital LLC lifted its position in shares of Vertex Pharmaceuticals by 4.5% in the first quarter. Quent Capital LLC now owns 513 shares of the pharmaceutical company's stock valued at $249,000 after acquiring an additional 22 shares in the last quarter. Sculati Wealth Management LLC lifted its position in Vertex Pharmaceuticals by 1.0% during the fourth quarter. Sculati Wealth Management LLC now owns 2,556 shares of the pharmaceutical company's stock worth $1,029,000 after buying an additional 25 shares in the last quarter. Avidian Wealth Enterprises LLC lifted its position in Vertex Pharmaceuticals by 2.1% during the first quarter. Avidian Wealth Enterprises LLC now owns 1,225 shares of the pharmaceutical company's stock worth $594,000 after buying an additional 25 shares in the last quarter. Strategic Blueprint LLC lifted its position in Vertex Pharmaceuticals by 1.7% during the first quarter. Strategic Blueprint LLC now owns 1,498 shares of the pharmaceutical company's stock worth $726,000 after buying an additional 25 shares in the last quarter. Finally, Breakwater Capital Group lifted its position in Vertex Pharmaceuticals by 1.5% during the first quarter. Breakwater Capital Group now owns 1,786 shares of the pharmaceutical company's stock worth $866,000 after buying an additional 27 shares in the last quarter. Institutional investors own 90.96% of the company's stock.

Vertex Pharmaceuticals Stock Down 0.7%

Shares of NASDAQ:VRTX opened at $459.81 on Friday. The firm has a market cap of $118.08 billion, a P/E ratio of -117.30 and a beta of 0.41. Vertex Pharmaceuticals Incorporated has a 12-month low of $377.85 and a 12-month high of $519.88. The business has a fifty day simple moving average of $449.49 and a 200 day simple moving average of $462.88. The company has a quick ratio of 2.29, a current ratio of 2.65 and a debt-to-equity ratio of 0.01.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last posted its quarterly earnings results on Monday, May 5th. The pharmaceutical company reported $4.06 EPS for the quarter, missing analysts' consensus estimates of $4.29 by ($0.23). Vertex Pharmaceuticals had a negative return on equity of 3.36% and a negative net margin of 8.91%. The company had revenue of $2.77 billion during the quarter, compared to analyst estimates of $2.85 billion. During the same quarter in the previous year, the business posted $4.76 earnings per share. The company's revenue for the quarter was up 2.6% compared to the same quarter last year. Analysts predict that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on VRTX. JPMorgan Chase & Co. lifted their price objective on Vertex Pharmaceuticals from $515.00 to $517.00 and gave the company an "overweight" rating in a research note on Monday, July 14th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $535.00 price objective on shares of Vertex Pharmaceuticals in a research report on Tuesday, May 6th. William Blair reaffirmed an "outperform" rating on shares of Vertex Pharmaceuticals in a research report on Tuesday, May 6th. Needham & Company LLC reaffirmed a "hold" rating on shares of Vertex Pharmaceuticals in a research report on Tuesday, May 6th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $550.00 price objective on shares of Vertex Pharmaceuticals in a research report on Monday, June 23rd. Fourteen analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Vertex Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average price target of $511.71.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.

Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.